What should be included in trimester history according to latest update
trimester history obstetric antenatal history taking components 2024 2025
trimester history components first second third
trimester history first second third antenatal components
NICE antenatal care trimester history taking first second third 2023 2024 guidelines
| Item | Detail |
|---|---|
| LMP & EDD | Last menstrual period date; estimated date of delivery (Naegele's rule or US dating) |
| Dating ultrasound | Crown-rump length at 11-13+6 weeks; confirm singleton vs. multiple gestation; chorionicity if twins |
| Booking visit | Gestation at first antenatal contact (ideally by 10 weeks) |
| Combined screening | Nuchal translucency + PAPP-A + free β-hCG (11-13+6 weeks) for Down syndrome/trisomies; result and counselling given |
| Booking bloods | FBC, blood group & Rh type, red cell antibodies, rubella immunity, syphilis, HIV, hepatitis B, haemoglobin electrophoresis (if indicated) |
| Urine culture | Mid-stream urine for asymptomatic bacteriuria |
| Symptoms | Nausea/vomiting (hyperemesis gravidarum), bleeding (threatened miscarriage, implantation), pelvic pain |
| Folic acid | Whether 400 mcg (or 5 mg high-dose) was taken pre-conception and throughout first trimester |
| Pre-eclampsia risk assessment | NICE NG201: assessed at booking; aspirin 75-150 mg from 12 weeks if high risk |
| Medications & teratogen exposure | First trimester is the critical period for organogenesis |
| Smoking, alcohol, drugs | Social history assessed at booking |
| Item | Detail |
|---|---|
| Anatomy (anomaly) scan | 18-20+6 weeks - cardiac, neural tube, abdominal wall defects, renal anomalies, placental location |
| Fetal movements | Onset of quickening (typically 16-20 weeks); whether normal |
| Serum screening (if not done) | Quadruple test (AFP, hCG, uE3, inhibin A) at 14-20 weeks if combined test not done |
| Cervical length | In women with prior preterm birth; cervical incompetence screening |
| Glucose challenge/GDM screening | 24-28 weeks (OGTT); risk assessment reviewed |
| Blood pressure checks | At each visit; re-assess pre-eclampsia risk (NICE NG201 recommends second risk assessment in second trimester) |
| Urine protein | Dipstick at each visit |
| Amniocentesis or CVS | If chromosomal testing elected; result and follow-up |
| Vaccinations | Pertussis (whooping cough) vaccine offered 16-32 weeks (ideally 20 weeks) in UK |
| Growth and placenta review | Placenta previa check at 20 weeks - if low-lying, arrange rescan at 32 weeks |
| Symptoms | Bleeding, discharge, pelvic girdle pain (symphysis pubis dysfunction), reflux, oedema |
| Item | Detail |
|---|---|
| Growth scans | Symphysis-fundal height (SFH) plotted at every visit from 24 weeks; growth scans if concern |
| Repeat bloods | FBC and blood group antibodies at 28 weeks; haemoglobin to check for anaemia |
| Rh prophylaxis | Anti-D immunoglobulin at 28 (and 34) weeks if Rh negative |
| GBS screening | Vaginal/rectal swab at 36-37+6 weeks (ACOG recommendation) |
| Fetal presentation | Checked from 36 weeks; breech - offer ECV at 36+ weeks |
| Fetal movements | Any reduction reported; kick counts or formal monitoring |
| CTG / biophysical profile | If high-risk or post-term |
| Repeat HIV, syphilis, HBV | In high-risk patients (CDC recommends 28-36 weeks) |
| Blood pressure + proteinuria | Continued at every visit - pre-eclampsia surveillance |
| Planned mode of delivery | Vaginal vs. caesarean discussed; birth plan |
| Gestational diabetes management | Blood glucose monitoring, insulin if required |
| Placenta previa | If persisting at 32-week rescan, plan for elective C-section |
| Vitamin K & breastfeeding discussions | Antenatal counselling |
| Influenza vaccine | Offered at any gestation |
| Mental health | Screen for antenatal anxiety/depression at every trimester |